Predictive Markers Useful in the Treatment of Wet Age-Related Macular Degeneration
Assigneemaintect GmbH
InventorsFranz Grus, Christina Korb, Norbert Pfeiffer
Life of this patent
Estimating the term…
Abstract
The invention is directed to the use of biomarkers to determine responsiveness of an individual with wet AMD to treatment with a VEGF antagonist, to diagnose and distinguish dry and wet AMD and to determine the risk of conversion of a dry AMD disease to a wet AMD disease.
Claims15
A method of determining the responsiveness of an individual with wet AMD to treatment with a VEGF antagonist, the method comprising:
- (i) isolating a sample from an individual having wet AMD;
- (ii) determining the quantity of one or several autoantibodies selected from Group A antibodies directed against MAPK3 , OGFR, PolyRp2, Chromosome 17, EIFA1, GPX4, SRP14, Gamma-synuclein, Jo-1, Pre-Albumin, GPD2, AP1M1, EN01-H7, PRG2, ATP synthase, GNB1-A3, TUBB3, HSP 60, ICA1, SELO, SOD, EN02 and
- (iii) assigning the individual as a VEGF antagonist responder if the sample has an increased or decreased amount of selected antibodies as in (ii), compared to a control.
(canceled)
(canceled)
A method of determining whether an individual suffers from dry AMD and/or wet AMD, the method comprising:
- isolating a sample from a subject;
- determining the quantity of one or several antibodies selected from Group B antibodies directed against alpha-synuclein, SELO, SPRY, GAPDH-H2, Annexin-V, THAP, VTI-B, HSP10, ESD, PKC80, AC02-C2, OGFR, PBP-I2, CAZ-C3, EIFA1, MAPK3, EN01-H7, Chromosome17, Aconitate Hydratase, GPX4;
- and
- determining that the individual suffers from the dry and/or the wet AMD disease if the amount of the selected Group B autoantibodies is increased or decreased, in particular increased or decreased by at least 20%, at least 30%, at least 40%, at least 50% or at least 75% compared to a control.
A method to determine that an individual with dry AMD is at risk to develop wet AMD, the method comprising:
- isolating a sample from a subject;
- determining the quantity of one or several antibodies selected from autoantibodies which are members of Group A and/or of Group B wherein Group A antibodies are directed against MAPK3, OGFR, PolyRp2, Chromosome 17, EIFA1, GPX4, SRP14, Gamma-synuclein, Jo-1, Prealbumin, GPD2, AP1M1, EN01-H7, PRG2, ATP synthase, GNB1-A3, TUBB3, HSP 60, ICA1, SELO, SOD, EN02 and wherein Group B antibodies are directed against alpha-synuclein, SELO, SPRY, GAPDH-H2, Annexin-V, THAP, VTI-B, HSP10, ESD, PKC80, AC02-C2, OGFR, PBP-I2, CAZ-C3, EIFA1, MAPK3, ENO1-H7, Chromosome17, Aconitate Hydratase, GPX4
- determining that the individual is at risk to develop wet AMD if the amount of the selected antibodies is decreased or increased, in particular decreased or increased by at least 20%, at least 30%, at least 40%, at least 50%, or at least 75% compared to control values.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.